Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-110 in CD70-positive advanced malignancies
NCT01813539Phase 2Completed
- Sponsor
- OncoVerity
- Start
- Feb 2013
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cusatuzumab in Neoplasm, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), hematological malignancy, solid tumor, sponsored by OncoVerity. Started Feb 2013; status: completed.
02
Drugs
cusatuzumab
03
Conditions
Neoplasmcutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)hematological malignancysolid tumor
Beyond the preview
Go deeper on NCT01813539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813539.